Functional characterization of antithrombin mutations by monitoring of thrombin inhibition kinetics

Abstract

Inactivation of thrombin by the endogenous inhibitor antithrombin (AT) is a central mechanism in the regulation of hemostasis. This makes hereditary AT deficiency, which is caused by SERPINC1 gene mutations, a major thrombophilic risk factor. Aim of this study was to assess to what extent AT mutations impair thrombin inhibition kinetics. The study population included 36 thrombophilic patients with 19 different mutations and mean AT levels of 65% in a thrombin‐based functional assay, and 26 healthy controls. To assess thrombin inhibition kinetics, thrombin (3.94 mU/mL final concentration) was added to citrated plasma. Subsequently, endogenous thrombin inhibition was stopped by addition of the reversible thrombin inhibitor argatroban and the amount of argatroban‐complexed thrombin quantified using an oligonucleotide‐based enzyme capture as-say. The plasma half‐life of human thrombin was significantly longer in patients with AT mutations than in the controls (119.9 versus 55.9 s). Moreover, it was disproportionately prolonged when compared with preparations of wild type AT in plasma, in whom a comparable thrombin half‐life of 120.8 s was reached at a distinctly lower AT level of 20%. These findings may help to better under-stand the increased thrombotic risk of SERPINC1 mutations with near normal AT plasma levels in functional assays.